RightFit
RecruitingPhase not listed

A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)

REal World ExperieNce With BRIUMVI® (UblituximAB-xiiy) Treated Patients: A Longitudinal REgistry Study (ENABLE)

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
18 Years and older
Sex
All sexes
Healthy volunteers
Not accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

Not stated in the study description — ask the study team about visits and procedures.

Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This study looks at the safety of BRIUMVI (ublituximab-xiiy), how well it works, and what treatment is like in everyday care. It is for people with relapsing multiple sclerosis (MS) who have been prescribed BRIUMVI but have not started it.

The purpose of this study is to evaluate safety, effiectiveness, and to gain insight into the treatment experience of participants prescribed BRIUMVI® (ublituximab-xiiy) in the real-world setting

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • You have a confirmed diagnosis of multiple sclerosis (MS).
  • You have not received any BRIUMVI infusions (medicine given into a vein) before the study starts. You may join if it has been prescribed but you have not yet received the first 150 mg dose.

Who can't join

  • You received a vaccine with live or weakened germs, such as a chickenpox or measles vaccine, within 4 weeks before your first BRIUMVI dose.
  • You received a vaccine without live germs within 2 weeks before your first BRIUMVI dose.
  • You have an active infection, such as hepatitis B.
  • You are also taking part in another MS study that tests a treatment.
  • You plan to use another medicine meant to change the course of MS during this study.

Simplified for readability. The official criteria below are what the study team uses.

Official eligibility criteria

Inclusion Criteria: 1. Confirmed Multiple Sclerosis (MS) diagnosis. 2. Participants who have not received any BRIUMVI® (ublituximab-xiiy) infusion prior to study start. Participants who have been prescribed BRIUMVI® (ublituximab-xiiy) but have not yet received their first infusion on Day 1 of 150 milligrams (mg) can be included. Exclusion Criteria: 1. Have received any live or live-attenuated vaccines (including for varicella-zoster virus or measles) within 4 weeks prior to first BRIUMVI® (ublituximab-xiiy) administration or any non-live vaccines within 2 weeks prior to first BRIUMVI® (ublituximab-xiiy) administration. 2. Any active infection (e.g., active Hepatitis B virus \[HBV\]) 3. Concurrent participation in any interventional MS trials, or planned concurrent treatment with other Multiple Sclerosis Disease Modifying Therapy (MS DMT) during the study period.

Study sites (109)

AL

AZ

CA

CO

CT

DC

FL

GA

HI

ID

IL

IN

KS

KY

MA

MD

MI

MN

MT

NC

NE

NJ

NV

NY

OH

OK

OR

PA

TN

TX

UT

VA

WA

WI

WV